362 related articles for article (PubMed ID: 23268703)
1. Ticagrelor: the first novel reversible P2Y(12) inhibitor.
Htun WW; Steinhubl SR
Expert Opin Pharmacother; 2013 Feb; 14(2):237-45. PubMed ID: 23268703
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
Cheng JW
Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.
Monitillo F; Iacoviello M; Caldarola P; Valle R; Chiatto M; Aspromonte N
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):977-93. PubMed ID: 25882759
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet options for secondary prevention in acute coronary syndromes.
Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
[TBL] [Abstract][Full Text] [Related]
5. Emerging oral antiplatelet therapies for acute coronary syndromes.
Pollack CV
Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
[TBL] [Abstract][Full Text] [Related]
6. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
Serebruany VL; DiNicolantonio JJ
Thromb Haemost; 2013 Jul; 110(1):5-10. PubMed ID: 23743577
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Norgard NB; Dinicolantonio JJ
Postgrad Med; 2013 Jul; 125(4):91-102. PubMed ID: 23933898
[TBL] [Abstract][Full Text] [Related]
9. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.
Ramaraj R; Movahed MR; Hashemzadeh M
J Interv Cardiol; 2011 Jun; 24(3):199-207. PubMed ID: 21198849
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
Anderson SD; Shah NK; Yim J; Epstein BJ
Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
[TBL] [Abstract][Full Text] [Related]
12. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
White HD
Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
[TBL] [Abstract][Full Text] [Related]
13. Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.
Berger JS
Am J Cardiol; 2013 Sep; 112(5):737-45. PubMed ID: 23751937
[TBL] [Abstract][Full Text] [Related]
14. Ticagrelor. Acute coronary syndromes: nothing new.
Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
Golino P
J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor: a review of its use in adults with acute coronary syndromes.
Dhillon S
Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive comparative review of adenosine diphosphate receptor antagonists.
Oh EY; Abraham T; Saad N; Rapp JH; Vastey FL; Balmir E
Expert Opin Pharmacother; 2012 Feb; 13(2):175-91. PubMed ID: 22216937
[TBL] [Abstract][Full Text] [Related]
19. P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.
Crouch MA; Colucci VJ; Howard PA; Spinler SA
Ann Pharmacother; 2011 Sep; 45(9):1151-6. PubMed ID: 21852599
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ; Clark SM
Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
